The mutation in huntingtin (mHtt) leads to a spectrum of impairments in the developing forebrain of Huntington's disease (HD) mouse models. Whether these developmental alterations are due to loss-or gainof-function mechanisms and contribute to HD pathogenesis is unknown. We examined the role of selective loss of huntingtin (Htt) function during development on postnatal vulnerability to cell death. We employed mice expressing very low levels of Htt throughout embryonic life to postnatal day 21 (Hdh 
Introduction
Cumulative studies have reported a plethora of early brain abnormalities in Huntington's disease (HD) that may reflect an impaired developmental substrate. These brain abnormalities may therefore represent the consequences of a developmental diathesis induced by aberrant polyglutamine expansion (polyQ) in huntingtin (Htt). These putative developmental sequelae include impairments in the inhibitory GABAergic system (Philpott et al., 2015) , oligodendrocyte abnormalities (Gomez-Tortosa et al., 2001; Myers et al., 1991) and white matter micro-architectural changes (Di Paola et al., 2014; Gregory et al., 2015; Phillips et al., 2014) , as well as region-specific brain volumetric alterations (Aylward et al., 2013; Nopoulos et al., 2011; Paulsen et al., 2006) . In line with these findings, we and other groups have reported significant developmental abnormalities in striatal and cortical neurogenesis in HD mice (Molero et al., 2009; Molina-Calavita et al., 2014) . Further, our in vitro studies using an embryonic stem cell line carrying mutant huntingtin (mHtt) demonstrates that this protein impairs the specification and maturation of organ-specific cellular lineages, as well as those of region-specific neural cellular subtypes (Nguyen et al., 2013a (Nguyen et al., , 2013b . Accordingly, recent transcriptomic studies have reported that genes with key developmental and neural functions are preferentially impacted in specimens carrying mHtt (Achour et al., 2015; Jin et al., 2012; Labadorf et al., 2015; Ng et al., 2013) . Neurobiology of Disease 96 (2016) 144-155 
